These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Abuse of pregabalin]. Bramness JG Tidsskr Nor Laegeforen; 2010 Sep; 130(17):1703-4. PubMed ID: 20835274 [No Abstract] [Full Text] [Related]
43. Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants. Lotarski SM; Donevan S; El-Kattan A; Osgood S; Poe J; Taylor CP; Offord J J Pharmacol Exp Ther; 2011 Aug; 338(2):615-21. PubMed ID: 21558437 [TBL] [Abstract][Full Text] [Related]
44. A case of pregabalin intoxication. Miljevic C; Crnobaric C; Nikolic S; Lecic-Tosevski D Psychiatriki; 2012; 23(2):162-5. PubMed ID: 22796916 [TBL] [Abstract][Full Text] [Related]
45. Pregabalin: a review of its use in adults with generalized anxiety disorder. Frampton JE CNS Drugs; 2014 Sep; 28(9):835-54. PubMed ID: 25149863 [TBL] [Abstract][Full Text] [Related]
46. [Abuse of pregabalin exists--but it's uncertain how often]. Lakartidningen; 2011 Aug 10-23; 108(32-33):1501. PubMed ID: 21922943 [No Abstract] [Full Text] [Related]
47. [The prescription registry and abuse of pregabalin]. Landmark CJ; Fossmark H; Larsson PG; Rytter E; Johannessen SI Tidsskr Nor Laegeforen; 2011 Feb; 131(3):223. PubMed ID: 21304565 [No Abstract] [Full Text] [Related]
48. The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo. Bauer CS; Rahman W; Tran-van-Minh A; Lujan R; Dickenson AH; Dolphin AC Biochem Soc Trans; 2010 Apr; 38(2):525-8. PubMed ID: 20298215 [TBL] [Abstract][Full Text] [Related]
49. The mechanisms of action of gabapentin and pregabalin. Sills GJ Curr Opin Pharmacol; 2006 Feb; 6(1):108-13. PubMed ID: 16376147 [TBL] [Abstract][Full Text] [Related]
50. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. Stevens JC; Pollack MH J Clin Psychiatry; 2005; 66 Suppl 2():21-7. PubMed ID: 15762816 [TBL] [Abstract][Full Text] [Related]
51. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. Gahr M; Franke B; Freudenmann RW; Kölle MA; Schönfeldt-Lecuona C J Addict Med; 2013; 7(2):147-9. PubMed ID: 23519046 [TBL] [Abstract][Full Text] [Related]
57. [Clinical experiences with pregabalin in the treatment of focal epilepsies]. Gil-Nagel Rein A; Gómez-Alonso J Rev Neurol; 2005 May 16-31; 40(10):609-13. PubMed ID: 15926135 [TBL] [Abstract][Full Text] [Related]
58. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. McClelland D; Evans RM; Barkworth L; Martin DJ; Scott RH BMC Pharmacol; 2004 Aug; 4():14. PubMed ID: 15294026 [TBL] [Abstract][Full Text] [Related]
59. [Pregabalin--clinical evidence and experiences]. Baron R Krankenpfl J; 2005; 43(7-10):204-5. PubMed ID: 16515276 [No Abstract] [Full Text] [Related]
60. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. Belliotti TR; Capiris T; Ekhato IV; Kinsora JJ; Field MJ; Heffner TG; Meltzer LT; Schwarz JB; Taylor CP; Thorpe AJ; Vartanian MG; Wise LD; Zhi-Su T; Weber ML; Wustrow DJ J Med Chem; 2005 Apr; 48(7):2294-307. PubMed ID: 15801823 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]